Related Experiment Video
Updated: May 17, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Advances in Hemophilia: New Treatments and Complications in Laboratory Testing/Monitoring
1University of Southern California, Keck School of Medicine, Los Angeles, CA, USA; Cancer and Blood Disorders Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Abstract:
The landscape of hemophilia treatment has recently undergone a drastic transformation with the advent of novel therapies, including extended half-life factor concentrates, nonfactor therapies, rebalancing agents, and gene therapies. While these advancements have improved patient outcomes, they have introduced challenges in laboratory monitoring. Traditional assays such as prothrombin time, activated partial thromboplastin time, and 1-stage clotting assays may not accurately reflect the hemostatic status in patients receiving these new treatments. This article reviews the evolution of hemophilia therapies and the corresponding challenges in laboratory testing, emphasizing the need for updated monitoring strategies to ensure optimal patient management.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

